You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers

    SBC: Syntrix Biosystems, Inc.            Topic: NIDA

    DESCRIPTION (provided by applicant): Tramadol is a widely prescribed analgesic, with over 25 million prescriptions and 565 million in retail sales in 2009, making it among the best selling generic drugs. One of the advantages of tramadol over traditionalopioids is its lower risk of opioid dependence, resulting in it having an unscheduled status in the U.S. and other countries. Although its mode ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  2. The Virtual Reality Functional Capacity Assessment Tool (VRFCAT) Validation Study

    SBC: NEUROCOG TRIALS            Topic: NIMH

    DESCRIPTION (provided by applicant): Schizophrenia is a devastating and costly mental illness with direct and unemployment costs approaching 95 billion per year. Cognitive impairments affect the majority of patients with schizophrenia. These impairments are strongly associated with poor long-term psychosocial outcomes and reflect a large and significant unmet clinical need. FDA approval of new dr ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  3. STAT Palm-Sized Blood Counter

    SBC: THE DNA MEDICINE INSTITUTE, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): The goal of this proposal is to develop a STAT palm-sized blood counter for monitoring complete blood counts (CBC) with 3-part differential during emergencies. Changes in blood counts can reflect acutely worsening medical conditions. For instance, a rapidly rising white blood cell count may occur during infections or a leukemic blast crises. Hematocrit values m ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  4. TP508: A New Drug for Mitigating Lethal Effects of Radiatin Exposure

    SBC: Chrysalis BioTherapeutics, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): With recent radiation release from reactors in Japan and increasing probability of nuclear detonation somewhere in the world, there is a critical need for development of effective medicinal counter-measures that can bedelivered after exposure to prevent radiation-induced mortality. Adding to this need, mortality increases significantly when radiation is combine ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  5. Mesenchymal Stem Cell Bioreactor for the Active Treatment of Acute Renal Failure

    SBC: Sentien Biotechnologies, Inc.            Topic: NIDDK

    DESCRIPTION (provided by applicant): The overall goal of this project is to design a clinical protocol for the operation and monitoring of a mesenchymal stem cell (MSC)-coated dialysis device for the treatment of acute renal failure (ARF) in dogs. The project specific aims are: (1) Biomarker-guided initiation of Sentinel therapy in an ARF dogs. (2) Execute a dose escalation trial of the Sentinel i ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  6. An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hyper

    SBC: Pulmokine, Inc.            Topic: NHLBI

    DESCRIPTION (provided by applicant): The purpose of this Phase II project is to develop a new treatment for pulmonary arterial hypertension (PAH) consisting of the inhaled platelet derived growth factor receptor (PDGFR) inhibitor PK10453. PAH is a diseaseof the pulmonary vasculature associated with high morbidity and mortality. Signaling through the PDGFR leads to smooth muscle cell proliferation ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  7. BIOMARKER FOR EARLY DETECTION OF CHRONIC KIDNEY DISEASE

    SBC: SEQUELA, INCORPORATED            Topic: NIDDK

    DESCRIPTION (provided by applicant): There are an estimated 26 million Americans with early chronic kidney disease (CKD). Early diagnosis and treatment are the only cost-effective means to reverse this growing problem. NIH recognizes the challenge to diagnose CKD early during its initiation and development phases in order to prevent further renal damage, reduce cardiovascular risk, and minimize th ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  8. Arm Motor Rehabilitation, Entertainment and Cognition System for the Elderly

    SBC: Bright Cloud International Corp            Topic: NIA

    DESCRIPTION (provided by applicant): It is hypothesized that the use robotic rehabilitation tables coupled with virtual reality games with elderly stroke survivors residents in skilled nursin facilities (SNFs) will: 1) improve and maintain upper extremityuni-manual and bimanual function, reach, strength and ADL independence; 2) improve and maintain cognition (memory, focus, problem solving); and ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  9. Portable electronically controlled transdermal patch for enfuvirtide delivery

    SBC: ACTUATED MEDICAL, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): In this Phase II NIH SBIR, Piezo Resonance Innovations will further optimize and test the Portable Transdermal Patch (PTP) - a needle-free platform delivery technology for drugs and vaccines that are currently deliveredsubcutaneously. The portable, 200gm (7oz) electronically-controlled transdermal patch for Enfuvirtide delivery employs a patented transducer tec ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  10. Dynamic Perturbation Training System for ACL Rehabilitation

    SBC: Simbex LLC            Topic: NICHD

    DESCRIPTION (provided by applicant): Anterior cruciate ligament (ACL) injuries are a significant problem for athletes, and women in particular. Both surgical and non-surgical treatment options exist, with the ultimate goal of regaining joint stability, knee kinematics, and quadriceps strength compared to the uninjured contralateral limb to allow full return of function and activity level and to p ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government